437 related articles for article (PubMed ID: 36769165)
1. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.
Yin X; Guo X; Liu Z; Wang J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769165
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease.
Powell EE; Wong VW; Rinella M
Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
[TBL] [Abstract][Full Text] [Related]
4. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
[TBL] [Abstract][Full Text] [Related]
5. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
6. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
Lake JE; Overton T; Naggie S; Sulkowski M; Loomba R; Kleiner DE; Price JC; Chew KW; Chung RT; Corey KE
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):256-268. PubMed ID: 33069882
[TBL] [Abstract][Full Text] [Related]
7. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
Tovoli F; Ferri S; Piscaglia F
Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
11. Pathology of non-alcoholic fatty liver disease.
Cataldo I; Sarcognato S; Sacchi D; Cacciatore M; Baciorri F; Mangia A; Cazzagon N; Guido M
Pathologica; 2021 Jun; 113(3):194-202. PubMed ID: 34294937
[TBL] [Abstract][Full Text] [Related]
12. From NAFLD to HCC: Advances in noninvasive diagnosis.
Xu Q; Feng M; Ren Y; Liu X; Gao H; Li Z; Su X; Wang Q; Wang Y
Biomed Pharmacother; 2023 Sep; 165():115028. PubMed ID: 37331252
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
15. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
[TBL] [Abstract][Full Text] [Related]
16. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
18. Current treatment paradigms and emerging therapies for NAFLD/NASH.
Raza S; Rajak S; Upadhyay A; Tewari A; Anthony Sinha R
Front Biosci (Landmark Ed); 2021 Jan; 26(2):206-237. PubMed ID: 33049668
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
Wang L; Liu XE; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
[TBL] [Abstract][Full Text] [Related]
20. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
